• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Searching for new targets for treatment of chemoresistant ovarian cancer.

Research Project

Project/Area Number 26462544
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Obstetrics and gynecology
Research InstitutionThe University of Tokyo (2015-2017)
National Cancer Center Japan (2014)

Principal Investigator

YAMAGUCHI Satoko  東京大学, 医学部附属病院, 特任助教 (40609872)

Co-Investigator(Kenkyū-buntansha) 毎田 佳子  国立研究開発法人国立がん研究センター, その他部局等, 研究員 (20397219)
Project Period (FY) 2014-04-01 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Keywords卵巣癌 / 薬剤耐性 / 機能的スクリーニング / shRNAライブラリー / 卵巣がん / 分子標的 / がん幹細胞 / 次世代shRNAライブラリー
Outline of Final Research Achievements

The aim of this study is to identify new targets for treatment of chemoresistant ovarian cancer. To achieve this aim, we performed a functional screening, taking advantage of a next generation shRNA library based on RNA interference. We screened for the genes whose inhibition results in growth inhibition or high sensitivity to cisplatin in chemoresistant ovarian cancer cells.
Cancer stem cells (CSCs) are considered to be one of the reasons for chemoresistance. We also found that eribulin mesylate, a compound that modulates microtubule dynamics, has high activity against ovarian cancer cells that exhibit high spheroid formation efficiency, a characteristic that might reflect cancer stem cell-like phenotype. We demonstrated that eribulin mesylate is likely to target telomerase catalytic subunit (hTERT), which has been reported to promote CSC-like traits.

Report

(5 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Research-status Report
  • 2015 Research-status Report
  • 2014 Research-status Report
  • Research Products

    (3 results)

All 2017 2015 2014

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results,  Acknowledgement Compliant: 1 results) Presentation (2 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Eribulin Mesylate Targets Human Telomerase Reverse Transcriptase in Ovarian Cancer Cells2014

    • Author(s)
      Satoko Yamaguchi, Yoshiko Maida, Mami Yasukawa, Tomoyasu Kato, Masayuki Yoshida, Kenkichi Masutomi
    • Journal Title

      PLOS one

      Volume: 9 Issue: 11 Pages: e112438-e112438

    • DOI

      10.1371/journal.pone.0112438

    • Related Report
      2014 Research-status Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Presentation] Searching for new treatments for ovarian cancer.2017

    • Author(s)
      Satoko Yamaguchi
    • Organizer
      10th HiHA international Workshop Cell Cycle Control and beyond
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] TERTを標的とした新たな卵巣癌分子標的治療の可能性2015

    • Author(s)
      毎田佳子
    • Organizer
      日本婦人科がん分子標的研究会
    • Place of Presentation
      長野県松本市
    • Year and Date
      2015-07-17 – 2015-07-18
    • Related Report
      2014 Research-status Report

URL: 

Published: 2014-04-04   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi